November 7, 2017 07:59 AM EST
Financing
Startups

Up­start Oys­ter Point has big plans for dis­rupt­ing the oph­thal­mol­o­gy space, but you'll have to wait for the de­tails

John Carroll

Editor & Founder

Tech­ni­cal­ly, Oys­ter Point Phar­ma­ceu­ti­cals is com­ing out of stealth mode to­day with a $22 mil­lion A round from NEA and Ver­sant that will fi­nance a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times